Aprea Therapeutics (NASDAQ:APRE) Shares Down 3.5% – Time to Sell?

Shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) traded down 3.5% on Thursday. The stock traded as low as $0.6750 and last traded at $0.7235. 772,588 shares traded hands during trading, an increase of 347% from the average daily volume of 172,868 shares. The stock had previously closed at $0.75.

Analyst Ratings Changes

A number of brokerages recently issued reports on APRE. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Friday, July 17th. Wedbush reduced their target price on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $3.07.

Aprea Therapeutics Price Performance

The stock has a market capitalization of $9.11 million, a price-to-earnings ratio of -0.67 and a beta of 1.66. The business has a fifty day moving average of $0.73 and a 200 day moving average of $0.77.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. On average, equities research analysts expect that Aprea Therapeutics, Inc. will post -0.34 EPS for the current year.

Institutional Trading of Aprea Therapeutics

A hedge fund recently raised its position in Aprea Therapeutics stock. AIGH Capital Management LLC boosted its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,015,541 shares of the company’s stock after buying an additional 645,000 shares during the period. AIGH Capital Management LLC owned approximately 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on restoring the function of mutated p53, a tumor-suppressor protein that is altered in many cancers and plays an important role in regulating cell growth and programmed cell death.

Aprea’s pipeline has included eprenetapopt (APR-246), an investigational therapy designed to reactivate mutant p53, as well as next-generation p53-reactivating compounds such as APR-548.